08/16
Headlines

ARIA

Whats Hot Today : Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Halliburton Company (NYSE:HAL), MWI Veterinary Supply, Inc. (NASDAQ:MWIV), K12, Inc. (NYSE:LRN), General Motors (NYSE:GM)

Jayne Crisman02 mins

On Oct 15, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is 6.53%. On last trading day company shares ended up $5.71. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) distance from…

Read More

Today’s Watch List : Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Oracle Corporation (NYSE:ORCL), JGWPT Holdings Inc. (NYSE:JGW), Argan, Inc. (NYSE:AGX), The Allstate Corporation (NYSE:ALL)

Mark Doerr02 mins

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with active brain metastases….

Read More

News Buzz : Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), VIVUS Inc. (NASDAQ:VVUS), Miller Energy Resources, Inc. (NYSE:MILL), RCS Capital Corporation (NYSE:RCAP), Fred’s, Inc. (NASDAQ:FRED),

Colin Pettis02 mins

Ariad Pharmaceuticals (NASDAQ:ARIA Director Sarah J. Schlesinger bought 5,200 shares of Ariad Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, September 10th. The shares were purchased at an average cost of $5.73 per share, with a total value of $29,796.00. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly…

Read More

Trader’s Recap : Ariad Pharmaceuticals (NASDAQ:ARIA), Trulia (NYSE:TRLA), Hawkins (NASDAQ:HWKN), Compugen Ltd. (NASDAQ:CGEN), Oaktree Capital Group, LLC (NYSE:OAK)

Jason Knox03 mins

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s Director Alexander J. Denner acquired 850,000 shares of Ariad Pharmaceuticals stock on the open market in a transaction dated Aug. 15. The shares were purchased at an average price of $5.83 per share, for a total transaction of $4,955,500.00. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is…

Read More